Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Operating Margin (2016 - 2025)

Historic Operating Margin for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to 4.92%.

  • Corcept Therapeutics' Operating Margin fell 206100.0% to 4.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.85%, marking a year-over-year decrease of 139600.0%. This contributed to the annual value of 20.29% for FY2024, which is 19500.0% down from last year.
  • Corcept Therapeutics' Operating Margin amounted to 4.92% in Q3 2025, which was down 206100.0% from 13.72% recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Operating Margin registered a high of 37.69% during Q3 2021, and its lowest value of 2.17% during Q1 2025.
  • Its 5-year average for Operating Margin is 22.97%, with a median of 24.72% in 2021.
  • Its Operating Margin has fluctuated over the past 5 years, first skyrocketed by 90600bps in 2021, then plummeted by -206100bps in 2025.
  • Over the past 5 years, Corcept Therapeutics' Operating Margin (Quarter) stood at 37.1% in 2021, then plummeted by -41bps to 21.83% in 2022, then rose by 7bps to 23.39% in 2023, then plummeted by -41bps to 13.89% in 2024, then crashed by -65bps to 4.92% in 2025.
  • Its last three reported values are 4.92% in Q3 2025, 13.72% for Q2 2025, and 2.17% during Q1 2025.